Whitehawk Therapeutics, Inc.
WHWKWhitehawk Therapeutics, Inc. in brief
Whitehawk Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Morristown, New Jersey, USA. Its market value was $189 M on 26 October 2026, which makes it the 16,455th largest listed company in the world and the 3,187th largest in the USA on this site. In the year to December 2025 it had sales of $7 M and a net loss of $21 M. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol WHWK (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Whitehawk Therapeutics, Inc.
We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization.
In December 2024, we entered into an intellectual property license agreement with WuXi Biologics (Shanghai FX) Co., Ltd. for the development and global commercialization of a portfolio of three next generation antibody drug conjugates targeting clinically validated, broadly overexpressed tumor antigens in high potential cancer indications with significant unmet need. These ADCs are constructed utilizing an advanced linker-payload platform called CPT113 that has been shown to provide increased stability in blood circulation and deliver targeted release of a Topoisomerase I inhibitor payload into cancer cells.
From the company's annual report filed with the US SEC: read the report
Whitehawk Therapeutics, Inc. timeline
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- ✎Renamed Aerpio Pharmaceuticals, Inc.Formerly Zeta Acquisition Corp Ii.
- 2021
- ✎Renamed Aadi Bioscience, Inc.Formerly Aerpio Pharmaceuticals, Inc..
- 2024
- 💰Record revenue of $26 millionFY2024, the highest of the 7 years on record.
- 2025
- ✎Renamed Whitehawk Therapeutics, Inc.Formerly Aadi Bioscience, Inc..
Events of Whitehawk Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 26.5×
- Price / book
- 1.4×
- Free cash flow yield
- -51.7%
- Net margin
- -288.5%
- Operating margin
- -1602.2%
- Return on equity
- -15.1%
- Liabilities / assets
- 9.6%
- Revenue growth
- -72.5%
- R&D / revenue
- 1273.9%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $7M | -72.5% | $-114M | $-21M | -288.5% |
| Dec 2024 | $26M | +6.7% | $-67M | $-64M | -245.2% |
| Dec 2023 | $24M | +60.0% | $-72M | $-66M | -270.1% |
| Dec 2022 | $15M | +8.7% | $-63M | $-61M | -397.6% |
| Dec 2021 | $14M | 0.0% | $-111M | $-110M | -786.4% |
| Dec 2020 | $14M | — | $-3M | $-3M | -24.9% |
| Dec 2019 | — | — | $-24M | $-23M | — |
| Dec 2018 | $20M | — | $-11M | $-10M | -51.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-97M | $1M | $-98M | $-0.33 | — |
| Dec 2024 | $-60M | $2M | $-61M | $-2.36 | — |
| Dec 2023 | $-60M | $4M | $-64M | $-2.44 | — |
| Dec 2022 | $-50M | $0M | $-50M | $-2.69 | — |
| Dec 2021 | $-22M | $0M | $-22M | $-12.41 | — |
| Dec 2020 | $-13M | $0M | $-13M | $-1.76 | — |
| Dec 2019 | $-24M | $0M | $-24M | $-0.57 | — |
| Dec 2018 | $-6M | $0M | $-6M | $-0.31 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-21M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Sep 10, 20268-KCurrent reportDirectors or officers changed
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 12, 20268-KCurrent reportShareholder vote
- May 21, 20268-KCurrent reportOther events
- May 13, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Apr 28, 2026DEF 14AProxy statement
- Mar 12, 202610-KAnnual report · period to Dec 2025
Official filings of Whitehawk Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $7 M
- Operating income
- $-114 M
- Net income
- $-21 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $151 M
- Total liabilities
- $15 M
- Total equity
- $136 M
As of December-2025
Top 91 institutional investors in Whitehawk Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Yu Fan | 4,829,398 | -31,916 (-0.66%) | 8.18% | $18 M | Nov 16, 2026 |
| 2 | Acuta Capital Partners, LLC | 4,685,912 | 0 (0.00%) | 7.94% | $18 M | Nov 16, 2026 |
| 3 | QVT Financial LP | 4,615,709 | 0 (0.00%) | 7.82% | $17 M | Nov 16, 2026 |
| 4 | Montanova Capital, LLC | 4,170,875 | -129,125 (-3.00%) | 7.07% | $16 M | Nov 16, 2026 |
| 5 | Orbimed Advisors LLC | 3,853,472 | -80,824 (-2.05%) | 6.53% | $14 M | Nov 16, 2026 |
| 6 | Avoro Capital Advisors LLC | 2,849,402 | 0 (0.00%) | 4.83% | $11 M | Nov 16, 2026 |
| 7 | BlackRock, Inc. | 2,589,723 | +666,895 (+34.68%) | 4.39% | $10 M | Nov 13, 2026 |
| 8 | Siren, L.L.C. | 2,337,102 | 0 (0.00%) | 3.96% | $9 M | Nov 12, 2026 |
| 9 | KVP Capital Advisors, LP | 2,165,997 | 0 (0.00%) | 3.67% | $8 M | Nov 16, 2026 |
| 10 | Vanguard Capital Management LLC | 1,465,827 | +77,266 (+5.56%) | 2.48% | $6 M | Nov 13, 2026 |
| 11 | ADAR1 Capital Management, LLC | 1,341,394 | 0 (0.00%) | 2.27% | $5 M | Nov 16, 2026 |
| 12 | Geode Capital Management, LLC | 1,055,562 | +155,782 (+17.31%) | 1.79% | $4 M | Nov 6, 2026 |
| 13 | Acorn Capital Advisors, LLC | 932,139 | -207,224 (-18.19%) | 1.58% | $4 M | Nov 16, 2026 |
| 14 | Renaissance Technologies LLC | 663,922 | +250,100 (+60.44%) | 1.13% | $2 M | Nov 12, 2026 |
| 15 | State Street Corp | 591,672 | +204,690 (+52.89%) | 1.00% | $2 M | Nov 12, 2026 |
| 16 | Two Sigma Investments, LP | 550,739 | +254,127 (+85.68%) | 0.93% | $2 M | Nov 16, 2026 |
| 17 | Woodline Partners LP | 507,061 | +70,447 (+16.13%) | 0.86% | $2 M | Nov 16, 2026 |
| 18 | Stempoint Capital LP | 495,980 | -525,057 (-51.42%) | 0.84% | $2 M | Nov 16, 2026 |
| 19 | Millennium Management LLC | 442,900 | +62,494 (+16.43%) | 0.75% | $2 M | Nov 16, 2026 |
| 20 | Acadian Asset Management LLC | 436,226 | +265,343 (+155.28%) | 0.74% | $2 M | Nov 9, 2026 |
| 21 | Northern Trust Corp | 329,303 | +64,614 (+24.41%) | 0.56% | $1 M | Nov 16, 2026 |
| 22 | Eversept Partners, LP | 303,171 | -135 (-0.04%) | 0.51% | $1 M | Nov 16, 2026 |
| 23 | Vanguard Portfolio Management LLC | 296,030 | +76,813 (+35.04%) | 0.50% | $1 M | Nov 13, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 283,605 | +36,698 (+14.86%) | 0.48% | $1 M | Nov 13, 2026 |
| 25 | Squarepoint Ops LLC | 206,513 | New | 0.35% | $1 M | Nov 9, 2026 |
Show all 91: investors 26 to 91
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Qube Research & Technologies Ltd | 197,064 | +148,071 (+302.23%) | 0.33% | $1 M | Nov 13, 2026 |
| 27 | Goldman Sachs Group Inc | 196,509 | +69,751 (+55.03%) | 0.33% | $1 M | Nov 16, 2026 |
| 28 | Verdad Advisers, LP | 153,698 | -147,785 (-49.02%) | 0.26% | $1 M | Nov 16, 2026 |
| 29 | Bridgeway Capital Management, LLC | 115,284 | -50,000 (-30.25%) | 0.20% | $0 M | Nov 16, 2026 |
| 30 | Charles Schwab Investment Management Inc | 105,867 | +27,035 (+34.29%) | 0.18% | $0 M | Nov 16, 2026 |
| 31 | Dimensional Fund Advisors LP | 105,011 | +71,591 (+214.22%) | 0.18% | $0 M | Nov 4, 2026 |
| 32 | Bank of New York Mellon Corp | 98,416 | +15,784 (+19.10%) | 0.17% | $0 M | Nov 5, 2026 |
| 33 | UBS Group AG | 78,502 | +27,661 (+54.41%) | 0.13% | $0 M | Nov 10, 2026 |
| 34 | Integrated Quantitative Investments LLC | 75,846 | New | 0.13% | $0 M | Nov 13, 2026 |
| 35 | Jump Financial, LLC | 71,400 | +30,600 (+75.00%) | 0.12% | $0 M | Nov 13, 2026 |
| 36 | American Century Companies Inc | 63,973 | +12,133 (+23.40%) | 0.11% | $0 M | Nov 12, 2026 |
| 37 | Morgan Stanley | 63,133 | +33,153 (+110.58%) | 0.11% | $0 M | Nov 13, 2026 |
| 38 | Nuveen, LLC | 54,530 | +10,731 (+24.50%) | 0.09% | $0 M | Nov 10, 2026 |
| 39 | FMR LLC | 43,933 | +43,763 (+25742.94%) | 0.07% | $0 M | Nov 10, 2026 |
| 40 | Invesco Ltd. | 43,888 | +4,709 (+12.02%) | 0.07% | $0 M | Nov 12, 2026 |
| 41 | HRT Financial LP | 43,614 | New | 0.07% | $0 M | Nov 13, 2026 |
| 42 | Deutsche Bank AG\ | 36,657 | +4,989 (+15.75%) | 0.06% | $0 M | Nov 6, 2026 |
| 43 | Bank Of America Corp /de/ | 35,726 | +1,100 (+3.18%) | 0.06% | $0 M | Nov 16, 2026 |
| 44 | XTX Topco Ltd | 35,666 | +17,144 (+92.56%) | 0.06% | $0 M | Nov 16, 2026 |
| 45 | Susquehanna Portfolio Strategies, LLC | 29,148 | New | 0.05% | $0 M | Nov 16, 2026 |
| 46 | Los Angeles Capital Management LLC | 28,380 | New | 0.05% | $0 M | Nov 12, 2026 |
| 47 | Price T Rowe Associates Inc /MD/ | 26,609 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 48 | MetLife Investment Management, LLC | 25,768 | New | 0.04% | $0 M | Nov 16, 2026 |
| 49 | Rhumbline Advisers | 25,108 | +579 (+2.36%) | 0.04% | $0 M | Nov 10, 2026 |
| 50 | Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 22,913 | New | 0.04% | $0 M | Oct 27, 2026 |
| 51 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 20,839 | +5,897 (+39.47%) | 0.04% | $0 M | Nov 16, 2026 |
| 52 | Jpmorgan Chase & Co | 20,752 | +7,179 (+52.89%) | 0.04% | $0 M | Nov 12, 2026 |
| 53 | Vanguard Global Advisers, LLC | 19,702 | +225 (+1.16%) | 0.03% | $0 M | Nov 13, 2026 |
| 54 | New York State Common Retirement Fund | 18,700 | 0 (0.00%) | 0.03% | $0 M | Nov 17, 2026 |
| 55 | Point72 Asset Management, L.P. | 18,012 | -39,117 (-68.47%) | 0.03% | $0 M | Nov 16, 2026 |
| 56 | Susquehanna Fundamental Investments, LLC | 17,500 | New | 0.03% | $0 M | Nov 16, 2026 |
| 57 | Barclays PLC | 17,321 | +10,888 (+169.25%) | 0.03% | $0 M | Nov 6, 2026 |
| 58 | Graham Capital Management, L.P. | 15,703 | New | 0.03% | $0 M | Nov 16, 2026 |
| 59 | Citadel Advisors LLC | 15,056 | -15,030 (-49.96%) | 0.03% | $0 M | Nov 16, 2026 |
| 60 | AQR Capital Management LLC | 13,543 | New | 0.02% | $0 M | Nov 16, 2026 |
| 61 | SEI Investments Co | 12,382 | New | 0.02% | $0 M | Nov 10, 2026 |
| 62 | Spark Investment Management LLC | 11,400 | New | 0.02% | $0 M | Nov 13, 2026 |
| 63 | Evergreen Capital Management LLC | 11,000 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 64 | BNP Paribas Financial Markets | 10,219 | +3,275 (+47.16%) | 0.02% | $0 M | Nov 12, 2026 |
| 65 | Police & Firemen's Retirement System of New Jersey | 10,205 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 66 | Wells Fargo & Company/mn | 8,469 | -18,705 (-68.83%) | 0.01% | $0 M | Nov 16, 2026 |
| 67 | Legal & General Group Plc | 4,152 | +990 (+31.31%) | 0.01% | $0 M | Nov 16, 2026 |
| 68 | US Bancorp \de\ | 3,333 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 69 | Russell Investments Group, Ltd. | 3,270 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 70 | Ameritas Investment Partners, Inc. | 2,945 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 71 | Tower Research Capital LLC (TRC) | 2,683 | +128 (+5.01%) | 0.00% | $0 M | Nov 16, 2026 |
| 72 | Royal Bank Of Canada | 2,385 | +1,271 (+114.09%) | 0.00% | $0 M | Nov 16, 2026 |
| 73 | Citigroup Inc | 2,130 | -12,889 (-85.82%) | 0.00% | $0 M | Nov 4, 2026 |
| 74 | Osaic Holdings, Inc. | 1,539 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 75 | Bartlett & Co. Wealth Management LLC | 1,333 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 76 | Sterling Capital Management LLC | 848 | +194 (+29.66%) | 0.00% | $0 M | Oct 22, 2026 |
| 77 | SBI Securities Co., Ltd. | 641 | +324 (+102.21%) | 0.00% | $0 M | Oct 22, 2026 |
| 78 | Parkside Financial Bank & Trust | 550 | New | 0.00% | $0 M | Oct 27, 2026 |
| 79 | Jones Financial Companies Lllp | 500 | New | 0.00% | $0 M | Nov 13, 2026 |
| 80 | SJS Investment Consulting Inc. | 405 | New | 0.00% | $0 M | Oct 26, 2026 |
| 81 | GAMMA Investing LLC | 286 | New | 0.00% | $0 M | Oct 8, 2026 |
| 82 | Allworth Financial LP | 250 | New | 0.00% | $0 M | Nov 17, 2026 |
| 83 | TD Waterhouse Canada Inc. | 232 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 84 | Farther Finance Advisors, LLC | 88 | New | 0.00% | $0 M | Oct 8, 2026 |
| 85 | Caitong International Asset Management Co., Ltd | 47 | -98 (-67.59%) | 0.00% | $0 M | Oct 29, 2026 |
| 86 | PNC Financial Services Group, Inc. | 39 | New | 0.00% | $0 M | Nov 6, 2026 |
| 87 | Root Financial Partners, LLC | 30 | New | 0.00% | $0 M | Oct 21, 2026 |
| 88 | Simplex Trading, LLC | 17 | -1 (-5.56%) | 0.00% | $0 M | Nov 4, 2026 |
| 89 | EverSource Wealth Advisors, LLC | 10 | New | 0.00% | $0 M | Nov 4, 2026 |
| 90 | Arax Advisory Partners | 8 | New | 0.00% | $0 M | Nov 12, 2026 |
| 91 | Parallel Advisors, LLC | 8 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
Mutual funds holding Whitehawk Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 887,972 | $4 M | 1.5% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 734,137 | $3 M | 1.2% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 470,854 | $2 M | 0.80% | <0.01% | +20% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 352,173 | $1 M | 0.60% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 281,712 | $1 M | 0.48% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 192,391 | $1 M | 0.33% | <0.01% | −1.7% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 110,575 | $1 M | 0.19% | 0.03% | +16% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 78,832 | $0 M | 0.13% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 62,161 | $0 M | 0.11% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 60,657 | $0 M | 0.10% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 57,711 | $0 M | 0.10% | <0.01% | −6.0% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 46,572 | $0 M | 0.08% | <0.01% | −7.3% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 45,075 | $0 M | 0.08% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 43,799 | $0 M | 0.07% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 34,206 | $0 M | 0.06% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 25,000 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 20,759 | $0 M | 0.04% | <0.01% | +2113% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 16,890 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 15,745 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 13,990 | $0 M | 0.02% | <0.01% | −30% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 15,506 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 13,000 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 9,220 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 9,165 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 7,372 | $0 M | 0.01% | 0.02% | +5.4% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 7,328 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 7,202 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 5,917 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 5,074 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 4,933 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 4,892 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 4,413 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 3,800 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,990 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,990 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 2,945 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 3,459 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 3,330 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 2,594 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,884 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 2,642 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 1,742 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation | 1,704 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust | 1,254 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,249 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 974 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 819 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 702 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 200 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 49 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Whitehawk Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Anupam DalalDirector | Grant or awardindirect | +1.28 M | $3.920 | $5.0 M | 4.69 M | Form 4 |
| filed | Caley CasteleinDirector | Grant or award | +255,102 | $3.920 | $1000 K | 274,796 | Form 4 |
| filed | Bryan BallSee remarks | Grant or award | +51,020 | $3.920 | $200 K | 448,126 | Form 4 |
| filed | Margaret DuganChief Medical Officer | Grant or award | +19,132 | $3.920 | $75 K | 19,132 | Form 4 |
| filed | David James LennonCHIEF EXECUTIVE OFFICER, Director | Grant or award | +51,021 | $3.920 | $200 K | 569,643 | Form 4 |
| filed | Scott M. GiacobelloCHIEF FINANCIAL OFFICER | Grant or award | +38,265 | $3.920 | $150 K | 333,489 | Form 4 |
| filed | Scott M. GiacobelloCHIEF FINANCIAL OFFICER | Sell | -141,600 | $4.130 | $585 K | 295,224 | Form 4 |
| filed | Scott M. GiacobelloCHIEF FINANCIAL OFFICER | Sell | -77,000 | $3.860 | $297 K | 436,824 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Whitehawk Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-14.99 reverse split
Trading halts
- 2025-03-19 13:32 UTC, code LUDP, resumed 13:37 UTC
Fails to deliver
- : 188 shares at $3.21
- : 61 shares at $3.70
- : 1,345 shares at $4.20
- : 68 shares at $4.39
- : 2,775 shares at $4.76
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Whitehawk Therapeutics, Inc. scorecard#
Passes 3 of the 18 checks that could be worked out: strongest in financial health (2 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.4×Price to book 1.4× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median26.5×Price to sales 26.5× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-51.7%Free cash flow is -51.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 6
- ✗Revenue grew in the newest year-72.5%Revenue down 72.5% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-22.3%-22.3% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-22.3%-22.3% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.33 vs -2.36Diluted EPS -0.33 in fiscal 2025 against -2.36 the year before (report's currency).
- ✗Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$3 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-21.8%-21.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities10.3×Current ratio 10.26 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone3.16Z-score 3.16 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year129.0%Diluted shares up 129.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Whitehawk Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Net margin | -288.5% | -68.9% | |
| Return on equity | -21.8% | -61.0% | |
| Revenue growth, 3 years a year | -22.3% | 12.9% | |
| Revenue growth | -72.5% | 15.8% |
3of 8on the Piotroski tests of financial strength
- Revenue fell 72.5% against the year before.
- Net loss of $21 million, the 16th loss-making year in a row.
- Free cash flow was negative: -$98 million.
- The share count rose 129.0% in the year.
Whitehawk Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 7.1−72.5%100% | 26+6.7%100% | 24+60.1%100% | 15+8.7%100% | 14r1.10.0%100% | 14r15—100% | 0−100%— | 20—100% | — | — | |
| Cost of revenue | 0.8−74.9%10.6% | 3.0+7.7%11.6% | 2.8+110%11.5% | 1.3—8.8% | 0—0.0% | — | — | — | — | — | |
| Research and development | 91+78.3%1273% | 51+4.3%196% | 49+49.8%201% | 33+66.0%215% | 20+31.1%141% | 15r13+17.0%107% | 13−28.2%— | 18+47.0%88.6% | 12+6.9%— | 11—— | |
| Selling, general and administrative | 30−18.8%417% | 37−17.5%141% | 45+10.9%183% | 40+117%264% | 19—132% | — | — | — | — | — | |
| General and administrative | — | — | — | — | 19+773%132% | 2.1r8.8−78.3%15.2% | 9.8−27.7%— | 13+45.9%66.9% | 9.2+75.5%— | 5.3r0.0—— | |
| Operating expenses | — | — | — | — | 112+556%802% | 17r21−29.9%122% | 24−22.0%— | 31+46.5%155% | 21+28.6%— | 17—— | |
| Total costs and expenses | 122+30.1%1701% | 93−3.0%360% | 96+23.6%395% | 78−30.7%512% | 112—802% | — | — | — | — | — | |
| Operating income | −114—−1601% | −67—−260% | −72—−295% | −63—−412% | −111—−794% | −2.5r−6.4—−18.2% | −24—— | −11—−55.5% | −21—— | −17r−0.0—— | |
| Interest and finance income | 6.2+58.8%87.2% | 3.9−38.7%15.1% | 6.4+167%26.3% | 2.4+18346%15.8% | 0.0−68.3%0.1% | 0.0—0.3% | — | — | — | — | |
| Interest expense and finance costs | 0−100%0.0% | 0.2−33.3%0.6% | 0.2+0.4%0.9% | 0.2−65.4%1.5% | 0.7−18.4%4.8% | 0.8—5.8% | — | — | — | 0.0—— | |
| Provision for credit losses | — | — | — | — | 0.2+2.4%1.2% | 0.2—1.2% | — | — | — | — | |
| Other non-operating income (expense) | 94+2390%1313% | 3.8−38.9%14.5% | 6.2+185%25.3% | 2.2+92.0%14.2% | 1.1−44.7%8.1% | 2.0+74.0%14.6% | 1.2+49.6%— | 0.8—3.9% | −0.0—— | −0.3—— | |
| Income before tax | −21—−288% | −64—−245% | −66—−270% | −61—−398% | −110—−786% | −3.5—−24.8% | — | — | — | — | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.00.0%0.0% | 0.0—0.0% | — | — | — | — | |
| Net income attributable to shareholders | −21—−288% | −64—−245% | −66—−270% | −61—−398% | −110—−786% | −3.5r−4.3—−24.8% | −23—— | −10—−51.6% | −21—— | −17r−0.0—— | |
| Earnings per share, basic | -0.33—— | -2.36—— | -2.44—— | -2.69—— | -12.41—— | -1.76r-0.10—— | -0.57—— | -0.31—— | -1.03—— | -24.52r-0.01—— | |
| Earnings per share, diluted | -0.33—— | -2.36—— | -2.44—— | -2.69—— | -12.41—— | -1.76r-0.10—— | -0.57—— | -0.31—— | -1.03—— | -24.52r-0.01—— | |
| Shares, weighted average (basic) | 62+129%— | 27+0.4%— | 27+19.6%— | 23+152%— | 8.9—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 62+129%— | 27+0.4%— | 27+19.6%— | 23+152%— | 8.9+251%— | 2.5r43−93.7%— | 41+19.6%— | 34+56.6%— | 22+2442%— | 0.9r5.0—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 38+31.0%24.9% | 29−54.4%40.8% | 63+61.2%47.5% | 39−73.8%21.2% | 149+3244%94.4% | 4.5r43−88.4%23.7% | 39−38.5%96.5% | 63+209%97.6% | 20+1159%96.4% | 1.6r0.0—67.2% | |
| Short-term investments | 108+482%71.7% | 19−59.6%26.4% | 46−65.6%34.7% | 134—72.5% | 0—0.0% | — | — | — | — | 0.1—2.1% | |
| Receivables | 0−100%0.0% | 5.9+7.6%8.4% | 5.5+195%4.1% | 1.9—1.0% | 0−100%0.0% | 14—75.2% | — | — | — | 0.0—0.2% | |
| Inventory | 0−100%0.0% | 5.3−17.4%7.6% | 6.4+245%4.9% | 1.9—1.0% | 0—0.0% | — | — | — | — | — | |
| Other current assets | 3.3+16.9%2.2% | 2.8−25.9%4.0% | 3.8+2.1%2.9% | 3.7+64.1%2.0% | 2.3+42.3%1.4% | 1.6+118%8.5% | 0.7+19.3%1.8% | 0.6+91.1%1.0% | 0.3+54.1%1.5% | 0.2—8.7% | |
| Current assets | 149+143%98.8% | 61−50.8%87.2% | 125−30.8%94.1% | 180+19.0%97.7% | 151+710%95.8% | 19r45−52.8%99.3% | 40−38.2%99.1% | 64+206%99.8% | 21+839%99.4% | 2.2—92.9% | |
| Property, plant and equipment | 0.0−100.0%0.0% | 6.8+42.6%9.7% | 4.8+845%3.6% | 0.5+791%0.3% | 0.1+171%0.0% | 0.0r0.1−87.2%0.1% | 0.2+66.8%0.4% | 0.1−8.2%0.2% | 0.1−28.3%0.5% | 0.1—6.2% | |
| Right-of-use (leased) assets | 0−100%0.0% | 0.8−32.7%1.1% | 1.2−23.2%0.9% | 1.5+173%0.8% | 0.6+368%0.4% | 0.1r0.1−26.6%0.6% | 0.2—0.4% | — | — | — | |
| Other intangible assets | — | — | — | 0−100%0.0% | 3.8—2.4% | 0—0.0% | — | — | — | — | |
| Total assets | 151+114%100% | 70−46.9%100% | 132−28.1%100% | 184+16.7%100% | 158+739%100% | 19r45−52.9%100% | 40−37.7%100% | 64+205%100% | 21+777%100% | 2.4r0.0—100% | |
| Accounts payable | 0.9−57.5%0.6% | 2.2−63.4%3.1% | 5.9+67.6%4.5% | 3.5−45.3%1.9% | 6.4+169%4.1% | 2.4r0.5+444%12.7% | 0.4−26.2%1.1% | 0.6−53.3%0.9% | 1.3+12.4%6.1% | 1.1r0.0—47.4% | |
| Current liabilities | 15−15.0%9.6% | 17−35.3%24.3% | 26+40.1%19.9% | 19+23.3%10.2% | 15−49.2%9.7% | 30r1.9+802%160% | 3.3−38.9%8.3% | 5.5+51.9%8.5% | 3.6−75.8%17.1% | 15r0.2—620% | |
| Lease liabilities (non-current) | 0−100%0.0% | 0.6−32.2%0.8% | 0.8−34.3%0.6% | 1.3+167%0.7% | 0.5—0.3% | — | 0.1—0.2% | — | — | — | |
| Total liabilities | 15−18.6%9.6% | 18−34.5%25.4% | 27+5.3%20.6% | 26+20.3%14.0% | 22−31.2%13.6% | 31r1.9+819%166% | 3.4−37.7%8.5% | 5.5—8.5% | — | — | |
| Retained earnings | −353—−234% | −333—−473% | −269—−203% | −203—−110% | −143—−90.4% | −33r−147—−173% | −142—−356% | −119—−186% | −109—−516% | −86r−0.3—−3597% | |
| Shareholders' equity | 136+160%90.4% | 52−50.1%74.6% | 105−33.6%79.4% | 158+16.1%86.0% | 136—86.4% | −12r43—−66.0% | −9.1r37−115%−22.8% | 59+236%91.5% | 17—82.9% | −86r−0.2—−3597% | |
| Total liabilities and equity | 151+114%100% | 70−46.9%100% | 132−28.1%100% | 184+16.7%100% | 158+739%100% | 19r45−52.9%100% | 40−37.7%100% | 64+205%100% | 21+777%100% | 2.4r0.0—100% | |
| Shares outstanding | 47+91.0%— | 25+0.5%— | 25+0.5%— | 24+16.9%— | 21+722%— | 2.5r47−93.7%— | 410.0%— | 41+49.9%— | 27+2081%— | 1.2r5.0—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.1−59.1%1.1% | 0.2+14.2%0.7% | 0.2+6.3%0.7% | 0.2+51.4%1.0% | 0.1+1067%0.8% | 0.0—0.1% | — | — | — | — | |
| Share-based compensation | 9.9−8.9%138% | 11−9.3%41.7% | 12+24.0%49.1% | 9.6+358%63.4% | 2.1+1415%15.0% | 0.1r1.3−87.2%1.0% | 1.1−68.4%— | 3.4+428%17.0% | 0.6+33.0%— | 0.5—— | |
| Cash from operating activities | −97—−1364% | −60—−229% | −60—−245% | −50—−326% | −22—−160% | −13r−5.4—−90.7% | −24—— | −5.8—−28.8% | −19—— | −0.0—— | |
| Capital expenditure | −0.6—−7.7% | −1.7—−6.4% | −4.0—−16.3% | −0.4—−2.9% | −0.0—−0.3% | −0.0—−0.1% | −0.2—— | −0.0—−0.2% | −0.0—— | −0.1—— | |
| Cash from investing activities | 12−52.8%166% | 25−69.7%97.0% | 83—342% | −133−628%−873% | 25—180% | −0.0—−0.1% | −0.2—— | −0.0−192%−0.2% | 0.0—— | −0.1—— | |
| Shares issued | — | — | — | 0−100%0.0% | 155+1491%1107% | 9.7—69.6% | — | 52+28.3%256% | 40—— | — | |
| Dividends paid | — | — | — | 0—0.0% | −4.4—−31.5% | — | — | — | — | — | |
| Cash from financing activities | 94+72497%1321% | 0.1−60.1%0.5% | 0.3−99.6%1.3% | 73−48.8%477% | 142+11776%1013% | 1.2r9.5—8.5% | — | 48+28.5%239% | 37+374868%— | 0.0—— | |
| Change in cash | 8.8—124% | −34−243%−132% | 24—98.0% | −110−176%−722% | 145—1032% | −12r4.1—−82.2% | −24−157%— | 42+127%210% | 19—— | −3.5r−0.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0−100%— | 0—— | 0—— | 0−100%— | 0*−100%— | 0−100%— | 0−100%— | 7.1+33.5%100% | 7.2*+14.4%100% | 7.2—100% | 6.2—100% | 5.4—100% | 6.3*—100% | |
| Cost of revenue | 0−100%— | 0—— | 0—— | 0−100%— | 0*−100%— | 0−100%— | 0−100%— | 0.8+16.6%10.6% | 0.8*−14.8%10.9% | 0.8—11.1% | 0.8—12.6% | 0.7—12.2% | 0.9*—14.7% | |
| Research and development | 67−22.0%— | 18+26.4%— | 13−73.6%— | 17+96.1%— | 19*+32.6%— | 14+43.5%— | 49+273%— | 8.8−35.3%123% | 14*+12.4%198% | 10.0—139% | 13—212% | 14—254% | 13*—202% | |
| Selling, general and administrative | 22−36.6%— | 4.8−7.6%— | 5.2−12.2%— | 6.3−50.9%— | 5.9*−46.9%— | 5.2−27.6%— | 5.9−24.7%— | 13+20.7%179% | 11*+6.8%153% | 7.2—99.6% | 7.9—128% | 11—198% | 10*—164% | |
| Total costs and expenses | 89−27.2%— | 23+17.4%— | 18−66.9%— | 24+5.2%— | 25*−5.0%— | 20−5.2%— | 55+152%— | 22−10.1%313% | 26*+8.9%362% | 21—286% | 22—352% | 25—465% | 24*—380% | |
| Operating income | −89—— | −23—— | −18—— | −24—— | −25*—— | −20—— | −55—— | −15—−213% | −19*—−262% | −13—−186% | −16—−252% | −20—−365% | −18*—−280% | |
| Interest and finance income | 6.2+16.1%— | 1.7−6.1%— | 1.5−25.5%— | 1.3+67.9%— | 1.6*+138%— | 1.9+104%— | 2.0+86.5%— | 0.8−38.3%11.1% | 0.7*−54.9%9.3% | 0.9—12.6% | 1.1—17.2% | 1.3—23.9% | 1.5*—23.7% | |
| Interest expense and finance costs | — | — | — | — | 0*—— | 0−100%— | 0−100%— | 0−100%0.0% | 0*−100%0.0% | 0.0—0.5% | 0.1—0.9% | 0.1—1.1% | 0.1*—0.9% | |
| Other non-operating income (expense) | 6.2−93.4%— | 1.7−3.7%— | 1.5−31.2%— | 1.3−98.5%— | 1.6*+142%— | 1.8+108%— | 2.1+113%— | 88+7115%1235% | 0.7*−53.2%9.3% | 0.9—12.0% | 1.0—16.2% | 1.2—22.8% | 1.4*—22.8% | |
| Income before tax | −83—— | −21—— | −17—— | −22−130%— | −23*—— | −18—— | −53—— | 73—1022% | — | — | — | — | −16*—−257% | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | |
| Net income attributable to shareholders | −83—— | −21—— | −17—— | −22−130%— | −23*—— | −18—— | −53—— | 73—1022% | −18*—−252% | −13—−174% | −15—−236% | −18—−342% | −16*—−257% | |
| Earnings per share, basic | — | -0.23—— | -0.20—— | -0.32−117%— | — | -0.26—— | -0.76—— | 1.84—— | — | -0.46—— | -0.54—— | -0.68—— | — | |
| Earnings per share, diluted | — | -0.23—— | -0.20—— | -0.32−117%— | — | -0.26—— | -0.76—— | 1.83—— | — | -0.46—— | -0.54—— | -0.68—— | — | |
| Shares, weighted average (basic) | 94+35.6%— | 94+35.6%— | 83+20.0%— | 69+74.7%— | — | 69+156%— | 69+156%— | 40+46.9%— | — | 27—— | 27—— | 27—— | — | |
| Shares, weighted average (diluted) | 94+35.6%— | 94+35.6%— | 83+20.0%— | 69+73.4%— | — | 69+156%— | 69+156%— | 40+48.0%— | — | 27—— | 27—— | 27—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 69—39.7% | 69+81.8%39.7% | 85−41.2%43.9% | 35−84.7%27.3% | 38+31.0%24.9% | 38+24.2%22.7% | 145+252%80.2% | 228+323%97.3% | 29−54.4%40.8% | 31—35.6% | 41—40.5% | 54—48.4% | 63—47.5% | |
| Short-term investments | 101—58.0% | 101−19.2%58.0% | 105+225%54.0% | 88+2427%69.4% | 108+482%71.7% | 125+289%74.6% | 32−13.8%17.8% | 3.5−89.9%1.5% | 19−59.6%26.4% | 32—37.4% | 37—36.8% | 34—31.1% | 46—34.7% | |
| Receivables | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 5.9+7.6%8.4% | 6.5—7.6% | 5.9—5.8% | 4.9—4.4% | 5.5—4.1% | |
| Inventory | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 5.3−17.4%7.6% | 5.5—6.4% | 6.1—6.0% | 5.9—5.3% | 6.4—4.9% | |
| Other current assets | 2.3—1.3% | 2.3−5.7%1.3% | 2.4+65.3%1.3% | 2.5+61.4%2.0% | 3.3+16.9%2.2% | 2.4−9.3%1.5% | 1.5−39.2%0.8% | 1.6−54.8%0.7% | 2.8−25.9%4.0% | 2.7—3.1% | 2.4—2.4% | 3.4—3.1% | 3.8—2.9% | |
| Current assets | 172—99.0% | 172+4.2%99.0% | 192+7.7%99.2% | 126−46.0%98.7% | 149+143%98.8% | 165+113%98.8% | 179+92.1%98.8% | 233+127%99.4% | 61−50.8%87.2% | 77—90.2% | 93—91.5% | 103—92.3% | 125—94.1% | |
| Property, plant and equipment | 0.0—0.0% | 0.0−25.0%0.0% | 0.0−88.9%0.0% | 0.0−92.0%0.0% | 0.0−100.0%0.0% | 0.0−99.9%0.0% | 0.0−99.9%0.0% | 0.0−99.6%0.0% | 6.8+42.6%9.7% | 6.0—7.0% | 6.0—5.9% | 5.7—5.1% | 4.8—3.6% | |
| Right-of-use (leased) assets | 0.2—0.1% | 0.2—0.1% | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.8−32.7%1.1% | 0.9—1.0% | 1.0—1.0% | 1.1—1.0% | 1.2—0.9% | |
| Total assets | 174—100% | 174+4.0%100% | 194+7.3%100% | 127−45.6%100% | 151+114%100% | 167+94.9%100% | 181+77.9%100% | 234+111%100% | 70−46.9%100% | 86—100% | 102—100% | 111—100% | 132—100% | |
| Accounts payable | 2.2—1.3% | 2.2+36.2%1.3% | 1.1−66.9%0.6% | 1.7−52.3%1.4% | 0.9−57.5%0.6% | 1.6+18.9%1.0% | 3.3+47.4%1.8% | 3.7+18.2%1.6% | 2.2−63.4%3.1% | 1.4—1.6% | 2.3—2.2% | 3.1—2.8% | 5.9—4.5% | |
| Current liabilities | 10—6.0% | 10+6.0%6.0% | 11+26.4%5.7% | 11−9.9%8.7% | 15−15.0%9.6% | 9.8−37.7%5.9% | 8.8−60.5%4.8% | 12−38.2%5.2% | 17−35.3%24.3% | 16—18.5% | 22—21.8% | 20—17.9% | 26—19.9% | |
| Lease liabilities (non-current) | 0.1—0.1% | 0.1—0.1% | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.6−32.2%0.8% | 0.6—0.7% | 0.7—0.7% | 0.7—0.7% | 0.8—0.6% | |
| Total liabilities | 11—6.1% | 11+6.9%6.1% | 11+26.4%5.7% | 11−9.9%8.7% | 15−18.6%9.6% | 9.8−41.5%5.9% | 8.8−61.6%4.8% | 12−40.5%5.2% | 18−34.5%25.4% | 17—19.6% | 23—22.5% | 21—18.6% | 27—20.6% | |
| Retained earnings | −413—−238% | −413—−238% | −392—−202% | −375—−295% | −353—−234% | −330—−198% | −312—−173% | −260—−111% | −333—−473% | −314—−367% | −302—−297% | −287—−259% | −269—−203% | |
| Shareholders' equity | 163—93.9% | 163+3.8%93.9% | 183+6.3%94.3% | 116−47.6%91.3% | 136+160%90.4% | 157+128%94.1% | 172+118%95.2% | 222+145%94.8% | 52−50.1%74.6% | 69—80.4% | 79—77.5% | 90—81.4% | 105—79.4% | |
| Total liabilities and equity | 174—100% | 174+4.0%100% | 194+7.3%100% | 127−45.6%100% | 151+114%100% | 167+94.9%100% | 181+77.9%100% | 234+111%100% | 70−46.9%100% | 86—100% | 102—100% | 111—100% | 132—100% | |
| Shares outstanding | 59—— | 59+25.2%— | 57+21.0%— | 47+0.9%— | 47+91.0%— | 47+91.5%— | 47+91.5%— | 47+90.5%— | 25+0.5%— | 25—— | 25—— | 25—— | 25—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | — | 0.1—0.9% | 0.0*—0.7% | |
| Share-based compensation | 7.8−16.0%— | 1.7−35.8%— | 1.5−50.8%— | 2.2+30.5%— | 2.4*+28.8%— | 2.7+6.3%— | 3.1+8.7%— | 1.7−53.2%23.5% | 1.9*−40.4%25.6% | 2.6—35.5% | 2.8—45.9% | 3.6—67.0% | 3.1*—49.2% | |
| Cash from operating activities | −74—— | −20*—— | −15*—— | −22—— | −17*—— | −15*—— | −53*—— | −12—−166% | −15*—−208% | −16*—−218% | −9.2*—−148% | −20—−367% | −9.6*—−152% | |
| Capital expenditure | −0.0—— | −0.0*—— | 0*—— | 0—— | 0*—— | 0*—— | −0.0*—— | −0.6—−7.7% | −0.2*—−2.6% | −0.2*—−2.6% | −0.5*—−8.8% | −0.7—−13.8% | −0.8*—−12.9% | |
| Cash from investing activities | 23+181%— | 3.6*—— | −17*—— | 19−83.2%— | 17*+28.3%— | −92*−1902%— | −29*—— | 115+994%1616% | 13*+260%181% | 5.1*—70.5% | −3.6*—−57.8% | 11—197% | 3.6*—57.7% | |
| Cash from financing activities | 82−13.5%— | −0.2*—— | 82*—— | 0−100%— | 0.0*−52.8%— | 0*—— | −0.9*−1077%— | 95—1332% | 0.1*−33.8%0.7% | 0*—0.0% | 0.1*—1.4% | −0.0—−0.2% | 0.1*—1.3% | |
| Change in cash | 31+323%— | −16*—— | 50*—— | −2.8−101%— | −0.4*—— | −107*—— | −83*—— | 199—2783% | −1.9*—−25.8% | −11*—−147% | −13*—−205% | −9.1—−170% | −5.9*—−93.5% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Whitehawk Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product sales, net(total)$7 M100%-73%
Business segments
- Reportable$7 M100%-73%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Whitehawk Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025David Lennon | $3.4 M | $4.5 M | $2.0 M | $19 |
| 2024Chief executive | $1.0 M | $1.6 M | $1.2 M | $25 |
| 2023Chief executive | $2.1 M | $1.1 M | $1.8 M | $16 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Whitehawk Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 4 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completed | 8-K | |
| Bylaws or fiscal year changedResults announced | 8-K | |
| Material agreementShareholder vote | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Restructuring | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2025 | $100 M | Private placement after listing | $50 to $250 million | 17 | equity, options | SEC |
| Sep 2022 | $73 M | Private placement after listing | $50 to $250 million | 13 | equity, options | SEC |
| Aug 2021 | $155 M | Private placement after listing | $50 to $250 million | 31 | equity | SEC |
| Mar 2017 | $42 M | Private placement after listing | $10 to $50 million | 264 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | 22 | · | · | · | · | 22 |
| 2021 | 7 | · | · | · | · | · | · | · | · | · | · | · | 7 |
| 2019 | · | · | · | 11 | · | · | · | · | · | · | · | · | 11 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 22 people (32% of workforce) | Restructuring planSEC 8-K | “(the “Company”) approved a plan of termination that will result in a workforce reduction of 22 employees, representing approximately 32% of the Company’s workforce.” | Filing | |
| 7 people (58% of workforce) | Restructuring planSEC 8-K | “The plan reduces its current workforce by 7 employees, representing approximately 58% of the Company’s workforce.” | Filing | |
| 11 people (41% of workforce) | Restructuring planSEC 8-K | “The realignment plan reduces its current workforce by 11 employees, representing approximately 41% of the Company’s workforce.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Whitehawk Therapeutics, Inc. compares in Biotechnology
- Market cap$189 M · higher than 44% of 726
- Revenue$7 M · higher than 39% of 647
- Net margin-288.5% · higher than 20% of 408
- Revenue growth-72.5% · higher than 9% of 438
- Price / sales26.5× · lower than 26% of 339
- Price / book1.4× · lower than 70% of 534
- FCF yield-51.7% · higher than 23% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Whitehawk Therapeutics, Inc.🇺🇸 | $189 M | — | -288.5% | -72.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Whitehawk Therapeutics, Inc.? Verify and update this profile — free
Show Whitehawk Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.